Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Airdoc 鹰瞳

Beijing Airdoc Technology Co., Ltd.

北京鷹瞳科技發展股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2251)

UPDATE ON FINANCIAL INFORMATION

This announcement is made by the board (the "**Board**") of directors of Beijing Airdoc Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on its preliminary assessment of the unaudited consolidated management accounts for the Group for the six months ended June 30, 2025 (the "**2025 Interim Period**") and information currently available to the management of the Group, the Board wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that the Group expects to record a net profit of no more than RMB0.5 million for the 2025 Interim Period as compared to the net loss of the Group of approximately RMB81.5 million for the corresponding period in 2024. Such change was mainly attributable to the following factors: (i) in terms of operational efficiency, the Company has adopted AI-driven solutions across its entire business chain, achieving improvements in operational efficiency from front-end customer acquisition to back-end services. Human-machine collaboration has shortened business turnaround cycles and enhanced the return on resource investment; (ii) in terms of cost control, by leveraging AI management tools, the Company has shifted from "passive cost-cutting" to "proactive efficiency enhancement," dynamically monitoring and precisely regulating core cost items such as procurement, human resources, and operations, thereby effectively reducing the proportion of non-core expenditures; and (iii) in terms of financial management, the Company strengthened credit period control, accelerated the turnover of accounts receivable, reduced capital occupation costs, and promoted financial stability.

The information contained in this announcement is unaudited and only based on a preliminary assessment by the Board with reference to the information currently available to the management, which has not been audited or reviewed by the independent auditors of the Company or confirmed by the audit committee of the Company, and thus may be subject to further adjustments and may differ from the figures to be disclosed in the interim results to be published by the Company.

As of the date of this announcement, the Company is still in the process of finalising the unaudited consolidated results for the 2025 Interim Period, which is expected to be published before the end of August 2025 in accordance with the requirements of the Listing Rules.

Shareholders and potential investors are advised not to place any reliance on the information disclosed herein but to exercise due caution when dealing in the securities of the Company.

By order of the Board
Beijing Airdoc Technology Co., Ltd.
Mr. ZHANG Dalei
Chairman of the Board

Hong Kong, August 20, 2025

As of the date of this announcement, the Board comprises Mr. ZHANG Dalei, Ms. WANG Lin, Mr. QIN Yong and Mr. WEI Yubo as executive Directors; and Dr. WU Yangfeng, Dr. HUANG Yanlin and Mr. NG Ho Yin Owen as independent non-executive Directors.